Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

Pacira will receive up to $140 million under the collaboration, including $70 million upfront plus up to $70 million in revenue-based milestone payments. The two companies will work together to advance the spasticity program, which modestly improves Pacira’s near-term cash flow visibility and development momentum.

Analysis

Pacira will receive up to $140 million under the collaboration, including $70 million upfront plus up to $70 million in revenue-based milestone payments. The two companies will work together to advance the spasticity program, which modestly improves Pacira’s near-term cash flow visibility and development momentum.